Astellas Pharma (ALPMY) Insider Trading & Ownership $9.79 +0.14 (+1.45%) (As of 12/20/2024 05:55 PM ET) Add Compare Share Share Insider Trades Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest There is no recent insider trading on record for Astellas Pharma, but the stock has been recently traded by U.S. Congress members, who may have more information about the industry than the general public. Get ALPMY Insider Trade Alerts Want to know when executives and insiders are buying or selling Astellas Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Behind the MarketsWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.Take these 4 steps today to protect your retirement NOW Astellas Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellAverage Share PriceTotal Transaction7/10/2023Daniel S. GoldmanU.S. Congress Member (D-NY)Sell$14.40$15,001 - $50,0002/27/2023Daniel S. GoldmanU.S. Congress Member (D-NY)Buy$14.09$15,001 - $50,0001/13/2023Daniel S. GoldmanU.S. Congress Member (D-NY)Sell$14.62$1,001 - $15,000 (Data available from 1/1/2013 forward) Astellas Pharma Key ExecutivesMr. Naoki Okamura BSc (Age 62)President, CEO & Director Compensation: $1.96MMr. Atsushi KitamuraSenior Executive Officer & CFONobue YasudaGeneral Manager of Finance & Accounting DepartmentMr. Yoshitsugu Shitaka Ph.D.Chief Scientific Officer & Senior Managing Executive OfficerMs. Catherine B. LevittGeneral CounselMr. Katsuyoshi Sugita (Age 57)Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director Mr. Stig OgataVice President of Corporate CommunicationsMs. Tatjana DragovicSenior VP and Head of Ethics & ComplianceMr. Nobuaki TanakaPresident of Japan Commercial & Senior Corporate ExecutiveJun KonoSenior Executive Officer & Head of Japan Commercial More Insider Trading Tools from MarketBeat Related Companies GSK Insider Buying TAK Insider Buying ALNY Insider Buying TEVA Insider Buying BGNE Insider Buying UTHR Insider Buying VTRS Insider Buying RPRX Insider Buying SMMT Insider Buying GMAB Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (OTCMKTS:ALPMY) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALPMY Stock Alerts